Adaptive biotechnologies stock.

Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS.In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by InstitutionsIn addition, Adaptive Biotechnologies Corporation has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal ...Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to …

Adaptive Biotechnologies ( ADPT -9.24%) is a biotech-adjacent stock that peaked in January and then fell hard. It's down 61% from its high-water mark, but the average analyst on Wall Street thinks ...May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ...

Nov 30, 2023 · Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ...

Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79.Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …It should be noted that over the last three months, corporate insiders have sold a total of 248,613 shares of Adaptive Biotechnologies stock, with a cumulative value of $2,006,083. As a result, corporate insiders now hold 5.20% of the company’s stock.Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ADPT Edit my quotes Adaptive Biotechnologies Corporation Common...

Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …

April 18, 2023 at 12:10 PM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation ( NASDAQ:ADPT) is a stock to potentially avoid ...

The upgrade of Adaptive Biotechnologies to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019, subject to the satisfaction of customary closing conditions. ... About Adaptive BiotechnologiesOf course Adaptive Biotechnologies may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders ...Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from the current ADPT share price of $4.37. SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ...

Apr 11, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61.

Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ...Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsSEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential …Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Beigene Ltd (BGNE) Stock Analysis: Promising Potential in Cancer Treatment and Positive Market Sentiment. Beigene Ltd (BGNE) is a biotechnology company that has gained attention from investors due to its promising potential in the field of cancer treatment. On November 7, 2023, the stock’s performance was closely monitored by analysts and ...Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...Andris Zoltners ADPT stock SEC Form 4 insiders trading. Andris has made over 2 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently Andris sold 345,000 units of ADPT stock worth $9,142,500 on 28 January 2020.. The largest trade Andris's ever made was selling 345,000 units of …

Adaptive Biotechnologies Corp is down 12.44% from its previous closing price of $7.96. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.87 and $8.10. Currently, there are 143.51 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …

Adaptive Biotechnologies is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus ...

Apr 18, 2023 · April 18, 2023 at 12:10 PM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation ( NASDAQ:ADPT) is a stock to potentially avoid ... Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...Ms. Rubinstein ADPT stock SEC Form 4 insiders trading. Julie has made over 40 trades of the Adaptive Biotechnologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 22,668 units of ADPT stock worth $194,265 on 6 March 2023.. The largest trade she's ever made was exercising 160,000 units of …Complete Adaptive Biotechnologies Corp. stock information by Barron's. View real-time ADPT stock price and news, along with industry-best analysis.Phone Number (206) 659-0067. Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection …The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price. Dec 1, 2022 · SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ... Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61.As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ...

The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price. Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment.Adaptive Biotechnologies (ADPT Quick Quote ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a ...Traditional biotechnology is the use of natural organisms by humans to create or modify foods or other useful products. Examples of traditional biotechnology include using yeasts for fermentation and practicing selective seed collection to ...Instagram:https://instagram. top investment books for beginnersbest ira for cryptodraft kings in floridaeuronet worldwide Nov 30, 2023 · Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... avantax ceterauber stock forecast Adaptive’s layoffs come as a hot biotech IPO market during 2021 cools down and biotech stock values decline. One key biotech index fund, the SPDR S&P Biotech ETF (XBI), is down about 50% from ... are there brokers for cryptocurrency SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range: 2 - 10Jul 10, 2023 · Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30-2023 at 4:30 PM EDT.